Altimmune (ALT) Liabilities and Shareholders Equity (2010 - 2026)

Altimmune (ALT) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $335.6 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 113.42% year-over-year to $335.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 65.81% YoY) and the FY2025 annual result came in at $279.9 million, up 100.95% from the prior year.
• Liabilities and Shareholders Equity advanced to $335.6 million in Q1 2026 per ALT's latest filing, from $279.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $335.6 million in Q1 2026 and bottomed at $139.3 million in Q4 2024.
• The 5-year median for Liabilities and Shareholders Equity is $190.4 million (2025), against an average of $201.5 million.
• The widest annual swing landed in 2024, when Liabilities and Shareholders Equity tumbled 33.87%; it then jumped 113.42% in 2026.
• Tracing ALT's Liabilities and Shareholders Equity over 5 years: stood at $206.9 million in 2022, then increased by 1.79% to $210.6 million in 2023, then sank by 33.87% to $139.3 million in 2024, then jumped by 100.95% to $279.9 million in 2025, then rose by 19.9% to $335.6 million in 2026.
• Per Business Quant, the three latest ALT Liabilities and Shareholders Equity figures stand at $335.6 million (Q1 2026), $279.9 million (Q4 2025), and $218.4 million (Q3 2025).

Peer Comparison